Protalix BioTherapeutics Inc [PLX] stock is trading at $2.53, up 6.75%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The PLX shares have gain 16.59% over the last week, with a monthly amount glided 45.40%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Protalix BioTherapeutics Inc [AMEX: PLX] stock has seen the most recent analyst activity on June 08, 2020, when H.C. Wainwright reiterated its Buy rating and also boosted its price target to $11 from $3. Previously, Rodman & Renshaw reaffirmed its Buy rating on April 17, 2017, and elevated its price target to $5. On April 04, 2016, Rodman & Renshaw initiated with a Buy rating and assigned a price target of $3.50 on the stock. Jefferies upgraded its rating to a Buy and increased its price target to $2.60 on April 23, 2015. R. F. Lafferty reiterated its recommendation of a Buy and reduced its price target to $5 on November 12, 2014. R. F. Lafferty started tracking with a Buy rating for this stock on January 24, 2014, and assigned it a price target of $8. In a note dated May 02, 2012, Oppenheimer reiterated an Outperform rating on this stock and boosted its target price from $9 to $11.
Protalix BioTherapeutics Inc [PLX] stock has fluctuated between $0.82 and $2.39 over the past year. Protalix BioTherapeutics Inc [AMEX: PLX] shares were valued at $2.53 at the most recent close of the market.
Analyzing the PLX fundamentals
Protalix BioTherapeutics Inc [AMEX:PLX] reported sales of 45.67M for the trailing twelve months, which represents a growth of 73.60%. Gross Profit Margin for this corporation currently stands at 0.36% with Operating Profit Margin at -0.2%, Pretax Profit Margin comes in at -0.21%, and Net Profit Margin reading is -0.21%. To continue investigating profitability, this company’s Return on Assets is posted at -0.16, Equity is -0.31 and Total Capital is -0.24. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.18.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.41 points at the first support level, and at 2.29 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.59, and for the 2nd resistance point, it is at 2.65.
Ratios To Look Out For
For context, Protalix BioTherapeutics Inc’s Current Ratio is 1.98. As well, the Quick Ratio is 1.27, while the Cash Ratio is 1.13. Considering the valuation of this stock, the price to sales ratio is 4.08, the price to book ratio is 5.74.
